All News
Evaluation of Bimekizumab in PsA
Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17A and F. There have been more updates on the 2 year data on BKZ at #ACR24, and this is a summary of four studies being presented this year at ACR24.
Read Article
A 6-year study of the link between alcohol consumption and spinal radiographic progression in axial spondyloarthritis (axSpA). Results indicate that alcohol may worsen spinal damage, particularly in males and those with radiographic axSpA. Future research should explore… https://t.co/IIvTyq7kBe
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Using #MachineLearning for predicting flares in axSpA @DiegoBenavent et al, data from METEOR-SpA registry showed the ff predictors of flares thru the reduced logistic regression model:
🔅lower ASDAS
🔅enthesitis
🔅prior flares
🔅longer treatment duration
@RheumNow #ACR24 abs559 https://t.co/wyIo9gnKVJ
sheila RHEUMarampa ( View Tweet)
📈 Data from @UIowa_Rheum on how rurality impacts delay to diagnosis in #GCA
📍 0747
👉🏼 People living in more rural areas have an increased time to diagnosis & treatment- further prospective studies needed to delineate effects of rurality further
@RheumNow #ACR24
@LemonReneeNi https://t.co/3YMcI9ha3T
Mrinalini Dey DrMiniDey ( View Tweet)
Harkins @DrTrishHarkins et al. People with PMR exhibit an accelerated physical aging phenotype at baseline. High rates of frailty (41%), pre-frailty (28%), cognitive impairment (74%!), sarcopenia (23%), osteoporosis (21%) @RheumNow #ACR24 Abstr#0740 https://t.co/4ZT8VtGi1W https://t.co/xBQ5CLlb5A
Links:
Richard Conway RichardPAConway ( View Tweet)
Does apremilast have cardiometabolic benefits?
Abstract 0598: In PsA patients, 1-year treatment with apremilast associated w/ ↓ body fat mass, including android fat, and was linked w/ improved disease activity (DAS28-CRP). #ACR24 @RheumNow https://t.co/11n4gQN7Xo
Akhil Sood MD AkhilSoodMD ( View Tweet)
#0588
🔬 Sex Differences in PsA
➡️n=1405, pooled RCT data
♀️49%: Milder PsO (PASI 7.8 v 11.5), higher BMI, longer PsA duration,⬆️ fatigue/pain vs ♂️
♀️worse QoL/functional impairment
♂️More dactylitis (45% v 37%)
🩺 Sex-specific factors matter in PsA
#ACR24 @RheumNow
Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
#0589
🔬Time to Response in PsA Domains: Secukinumab
➡️Post-hoc analyses, n=1366
🔑Median time (wks) to MCID 👇
🔴Systemic inflammation <2
🔴MSK: ~4 wks (enthesitis~12)
🔴Fatigue~7–8
🔴PASI75~8–12; nails ~24
🩺 Rapid MSK & QoL benefits precede skin/nail
#ACR24 @RheumNow https://t.co/WfqkryA1CC
Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
Switching vs cycling - which is better? In PsA & axSpA, a real-world analysis shows that switching to IL-17Ai after TNFi discontinuation may lead to similar or better outcomes compared to cycling to another TNFi. Data from the CorEvitas PsA/SpA Registry. Abstr#0585.… https://t.co/AJP4NBjmzr
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
De Lorenzis et al. MMF in LcSSc. Target Trial Emulation. 1435 patients. Incidence vasodilator treatment escalation over 41 months, 1/100py in MMF vs 7.3/100py in controls. @RheumNow #ACR24 Abstr#0688 https://t.co/D3qTUHyIIc https://t.co/6azvaS0ElL
Links:
Richard Conway RichardPAConway ( View Tweet)
Galloway et al report OCP/HRT use in RA is not associated with VTE in UK population based study. Increased risk by having RA, HR 1.52. Risk OCP HR 1.43, HRT HR 2.32 - neither statistical significant but very wide CI's! Hmm... @RheumNow #ACR24 Abstr#0134 https://t.co/CZNoRfYWe8 https://t.co/uC6jA9lcX9
Links:
Richard Conway RichardPAConway ( View Tweet)
🧬 #SLE patients show major community mobility limits: 50% don't leave their neighborhood weekly without help. Life Space Assessment finds lower mobility vs. other chronic conditions. Better mobility linked to higher SES & lower disease activity. @RheumNow #ACR24 abst#0145 https://t.co/2sfXNlJ9JD
Bella Mehta bella_mehta ( View Tweet)
Data from the French DESIR cohort reveals no significant link between high-dose NSAID use and incident hypertension in patients with axial spondyloarthritis. Two thirds were high dose NSAID users at baseline. Incident hypertension occurred in 11% individuals during follow-up.… https://t.co/EAICDwzxNT
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Serrano-Combarro et al. Abatacept in RA-ILD. 343 patients. In 23.3% ILD progressed on abatacept. Is that good or bad? We need comparative studies! @RheumNow #ACR24 Abstr#0475 https://t.co/nUEDdjGguA https://t.co/sXEF72MafK
Links:
Richard Conway RichardPAConway ( View Tweet)
Cannabis and Physical Function
Very small effects on meta-analysis
PO cannabis - 4% benefit (0.1-8%) of achieving at least MID of SF36 function scale
16S18 @BharatKumarMD
#ACR24 @RheumNow https://t.co/qQOYt1m3ub
Eric Dein ericdeinmd ( View Tweet)
Prevalence of HLH among pts w/SLE: lower than consults would suggest!
Observational study using NIS: 139 cases out of >100k pts w/SLE (0.13%); 6 fold increase in mortality
Fits my priors; HLH is overdiagnosed, but bad when it happens
@RheumNow #ACR24 Abstr#0619 https://t.co/iz3BlUOJb9
Mike Putman EBRheum ( View Tweet)
Is biologic response different in men vs women with axSpA?
A Meta-analysis of 11 studies including 11,199 axSpA pts evaluated sex-related response to bDMARDs
-Male pts more likely to achieve BASDAI 50 and ASDAS low disease activity responses compared to females.
#Abst0599… https://t.co/FopBLS4bF6 https://t.co/PpoZB9HwZN
Links:
Adela Castro AdelaCastro222 ( View Tweet)
Another abstract #0650 highlighting the impact of tubulointerstitial inflammation predicting risk of CKD/ESRD in lupus nephritis
@RheumNow #ACR24 https://t.co/XYwO0xnWNR
Akhil Sood MD AkhilSoodMD ( View Tweet)
Older adults with RA receive less DMARDs, the standard of care. Dr. Bruno Fautrel shows TOC tolerance in older adults is comparable to younger patients. Let's treat the patient, not their age! #ACR24 @RheumNow ABST#0516 https://t.co/054RWGh3a7
Jiha Lee JihaRheum ( View Tweet)
Cardiology 🤝 Rheumatology
#Abstract0611 highlights Subclinical atherosclerosis (carotid plaque > 1.5 mm) associated with ↑ risk of CV events in SLE longitudinal cohort
@RheumNow #ACR24 https://t.co/jLLYNOfFZ2
Akhil Sood MD AkhilSoodMD ( View Tweet)
